Company Overview
| Stock Name | Raily Aesmed |
|---|---|
| Stock Code | 02135 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 於中國浙江省提供醫療美容服務,包括美容外科服務、微創美容服務及皮膚美容服務,並提供醫療美容管理諮詢服務。 |
| Listing Date | 2020-12-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國杭州下城區中山北路290號民航大廈3–5樓 |
| Business Address (Hong Kong) | 香港皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | ruilizx.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 0.40 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 10,000 shares |
| Entry Threshold | HK$ 4,000 |
| Par Value | To be extracted |
| Offer Period | 2020-12-15 to 2020-12-18 |
| Global Offering Shares | 342,500,000 shares |
| HK Public Offer Shares (Initial) | 34,250,000 shares (10.0%) |
| Public Offer Lots (Initial) | 3,425lots (Pool A1,712lots,Pool B1,713lots) |
| International Placing Shares (Initial) | 308,250,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 2,055,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 21.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 137,000,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 10,000 | HK$ 4,000 |
| 2 lots | 20,000 | HK$ 8,000 |
| 3 lots | 30,000 | HK$ 12,000 |
| 4 lots | 40,000 | HK$ 16,000 |
| 5 lots | 50,000 | HK$ 20,000 |
| 6 lots | 60,000 | HK$ 24,000 |
| 7 lots | 70,000 | HK$ 28,000 |
| 8 lots | 80,000 | HK$ 32,000 |
| 9 lots | 90,000 | HK$ 36,000 |
| 10 lots | 100,000 | HK$ 40,000 |
| 20 lots | 200,000 | HK$ 80,000 |
| 30 lots | 300,000 | HK$ 120,000 |
| 40 lots | 400,000 | HK$ 160,000 |
| 50 lots | 500,000 | HK$ 200,000 |
| 60 lots | 600,000 | HK$ 240,000 |
| 70 lots | 700,000 | HK$ 280,000 |
| 80 lots | 800,000 | HK$ 320,000 |
| 90 lots | 900,000 | HK$ 360,000 |
| 100 lots | 1,000,000 | HK$ 400,000 |
| 200 lots | 2,000,000 | HK$ 800,000 |
| 300 lots | 3,000,000 | HK$ 1,200,000 |
| 400 lots | 4,000,000 | HK$ 1,600,000 |
| 500 lots | 5,000,000 | HK$ 2,000,000 |
| 600 lots | 6,000,000 | HK$ 2,400,000 |
| 700 lots | 7,000,000 | HK$ 2,800,000 |
| 800 lots | 8,000,000 | HK$ 3,200,000 |
| 900 lots | 9,000,000 | HK$ 3,600,000 |
| 1,000 lots | 10,000,000 | HK$ 4,000,000 |
| 1,200 lots | 12,000,000 | HK$ 4,800,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,400 lots | 14,000,000 | HK$ 5,600,000 |
| 1,600 lots | 16,000,000 | HK$ 6,400,000 |
| 1,712 lots | 17,120,000 | HK$ 6,848,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 63.9M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +15105% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 822,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣10.3百萬元 |
| Period-End Cash Balance | 人民幣49.4百萬元 |
| Listing Expenses | ~HK$ 63,900,000 |
| Listing Expenses / Funds Raised | ~46.64% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2017 | 2018 | 2019 |
|---|---|---|---|
| Revenue | 112,932 | 158,935 | 191,156 |
| Cost of sales | -38,390 | -66,442 | -90,118 |
| Gross profit | 74,542 | 92,493 | 101,038 |
| Other income and gains, net | 65 | 592 | 1,626 |
| Selling and distribution expenses | -37,020 | -44,667 | -50,172 |
| Administrative expenses | -12,392 | -18,489 | -33,405 |
| Operating profit | 24,693 | 29,674 | 18,724 |
| Net finance costs | -1,361 | -3,291 | -2,336 |
| Profit before tax | 23,332 | 26,383 | 16,388 |
| Income tax expense | -5,927 | -7,965 | -6,111 |
| Profit for the year | 17,405 | 18,418 | 10,277 |
| Profit attributable to owners | 17,379 | 17,855 | 9,897 |
Balance Sheet
| Item | 2017 | 2018 | 2019 | 2020-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 9,418 | 20,355 | 49,410 | |
| Trade and bills receivables | 4,381 | 5,097 | 8,321 | |
| Total current assets | 32,389 | 42,599 | 93,307 | |
| Total current liabilities | 54,858 | 81,010 | 70,068 | |
| Total equity | 15,667 | 14,990 | 93,275 | |
| Equity attributable to owners | 16,281 | 15,041 | 93,058 | |
| Interest-bearing borrowings | 0 | 0 | 6,948 | 15,005 |
Cash Flow Statement
| Item | 2017 | 2018 | 2019 | 2020-06 |
|---|---|---|---|---|
| Net cash from operating activities | 34,548 | 32,057 | 16,981 | |
| Depreciation of PP&E | 4,295 | 4,908 | 5,784 | 3,640 |
| Depreciation of right-of-use assets | 3,182 | 3,585 | 5,902 | 2,920 |
| Amortisation of intangible assets | 31 | 55 | 67 | 16 |
| Purchase of PP&E | -2,611 | -12,723 | -10,832 | -1,567 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 0.435 |
|---|---|
| First Day Open | HK$ 0.475 |
| First Day Change | 8.75% |
| First Day Volume | 819968000.0 |
| First Day Turnover | 386834000.0 |
| Use of Proceeds | 1、約28.0%,或19.7百萬港元,將用作翻新所有現有醫療美容機構并擴張杭州瑞麗、瑞麗天鴿及蕪湖瑞麗,以提升能力、更新品牌形象及擴大市場份額;
2、約28.0%,或19.7百萬港元,將用作為上海市新建醫療美容機構的資本支出及初始營運成本提供資金;
3、約15.0%,或10.6百萬港元,將用作中國浙江省醫療美容機構的潛在戰略收購;
4、約11.0%,或7.8百萬港元,將用作購買醫療美容服務設備及醫療消耗品,以完善若干醫療美容診療,擴大醫療美容服務范圍;
5、約8.0%,或5.6百萬港元將用于積極推廣我們的品牌;
6、約10%,或7.0百萬港元,將用作一般營運資金及其他一般公司用途。 |
Underwriting Syndicate
Sole Sponsor (1)
INNOVAX CAPITAL LIMITED CE BDT371
Overall Coordinators (2)
Joint Bookrunners (5)
Joint Lead Managers (9)
AUSTRAX SECURITIES LIMITED CE BHV052
Apricot Capital (Hong Kong) Limited CE ACX624
交银国际证券有限公司 CE APJ121
SDIC SECURITIES (HONG KONG) LIMITED CE AUW685
First Fidelity Capital (International) Limited CE AMS441
Kirin Securities Limited CE BJB225
KINGKEY SECURITIES GROUP LIMITED CE AXG710
Realord Asia Pacific Securities Limited CE AVJ441
IMPERIUM INTERNATIONAL SECURITIES LIMITED CE AVI905
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 昊海生物科技控股有限公司 | 20,000,000 HKD | — | 14.60% | — | 6 months | 2021-06-28 |
| 2 | 途益香港有限公司 | 10,000,000 HKD | — | 7.30% | — | 6 months | 2021-06-28 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 傅海曙 | — |
| Company Secretary | 陳愛發 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 傅海曙先生透過Ruide BVI間接持有本公司約53.98%股份;Ruide BVI為其全資投資控股公司,傅先生配偶金春苗女士被視為持有相同權益。其他主要股東包括美天下(6.28%)、上海東嫿(5.46%)及Huamei Medical(5.46%)等。 |
|---|




